{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:10:05Z","timestamp":1751533805870,"version":"3.41.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Support Plan for Youth Innovation in Universities of Shandong Province","award":["2023KJ032"],"award-info":[{"award-number":["2023KJ032"]}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["24PTLYHZ00280"],"award-info":[{"award-number":["24PTLYHZ00280"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02804-3","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:55:50Z","timestamp":1748969750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition"],"prefix":"10.1007","volume":"42","author":[{"given":"Huiying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Dan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wennan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"5","key":"2804_CR1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"7","key":"2804_CR2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6467","key":"2804_CR3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366(6467):818\u201322.","journal-title":"Science"},{"key":"2804_CR4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","volume":"87","author":"JAM Bard","year":"2018","unstructured":"Bard JAM, Goodall EA, Greene ER, et al. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87:697\u2013724.","journal-title":"Annu Rev Biochem"},{"issue":"32","key":"2804_CR5","doi-asserted-by":"crossref","first-page":"E4639","DOI":"10.1073\/pnas.1608644113","volume":"113","author":"O Braten","year":"2016","unstructured":"Braten O, Livneh I, Ziv T, et al. Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination. Proc Natl Acad Sci U S A. 2016;113(32):E4639-4647.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2804_CR6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers11010066","volume":"11","author":"MHZ Guang","year":"2019","unstructured":"Guang MHZ, Kavanagh EL, Dunne LP, et al. Targeting proteotoxic stress in cancer: a review of the role that protein quality control pathways play in oncogenesis. Cancers (Basel). 2019;11(1):66.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2804_CR7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/cancers13061235","volume":"13","author":"T Paradzik","year":"2021","unstructured":"Paradzik T, Bandini C, Mereu E, et al. The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers (Basel). 2021;13(6):1235.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2804_CR8","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1681\/ASN.2006010083","volume":"17","author":"SH Lecker","year":"2006","unstructured":"Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006;17(7):1807\u201319.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2804_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","volume":"1843","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta. 2014;1843(1):13\u201325.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2804_CR10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, et al. Proteasome inhibitors\u2014molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947\u201361.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"2804_CR11","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22894","volume":"35","author":"J Wang","year":"2021","unstructured":"Wang J, Wang Y, He S, et al. Proteasome inhibition induces macrophage apoptosis via mitochondrial dysfunction. J Biochem Mol Toxicol. 2021;35(11): e22894.","journal-title":"J Biochem Mol Toxicol"},{"issue":"8","key":"2804_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.7150\/jca.11785","volume":"6","author":"M Zhang","year":"2015","unstructured":"Zhang M, Yuan X, Xu B, et al. Anticancer effect of a novel proteasome inhibitor, YSY01A, via G2\/M arrest in PC-3M cells in vitro and in vivo. J Cancer. 2015;6(8):701\u20138.","journal-title":"J Cancer"},{"issue":"3","key":"2804_CR13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.onc.1208225","volume":"24","author":"D Yin","year":"2005","unstructured":"Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005;24(3):344\u201354.","journal-title":"Oncogene"},{"key":"2804_CR14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.sbi.2019.10.004","volume":"61","author":"ER Greene","year":"2020","unstructured":"Greene ER, Dong K, Martin A. Understanding the 26S proteasome molecular machine from a structural and conformational dynamics perspective. Curr Opin Struct Biol. 2020;61:33\u201341.","journal-title":"Curr Opin Struct Biol"},{"key":"2804_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.sbi.2020.10.010","volume":"67","author":"C Davis","year":"2021","unstructured":"Davis C, Spaller BL, Matouschek A. Mechanisms of substrate recognition by the 26S proteasome. Curr Opin Struct Biol. 2021;67:161\u20139.","journal-title":"Curr Opin Struct Biol"},{"issue":"3","key":"2804_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molcel.2008.03.004","volume":"30","author":"J Rabl","year":"2008","unstructured":"Rabl J, Smith DM, Yu Y, et al. Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases. Mol Cell. 2008;30(3):360\u20138.","journal-title":"Mol Cell"},{"issue":"6","key":"2804_CR17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.molcel.2019.01.018","volume":"73","author":"Z Ding","year":"2019","unstructured":"Ding Z, Xu C, Sahu I, et al. Structural snapshots of 26S proteasome reveal tetraubiquitin-induced conformations. Mol Cell. 2019;73(6):1150-1161.e6.","journal-title":"Mol Cell"},{"issue":"4","key":"2804_CR18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13277-011-0177-2","volume":"32","author":"D Hempel","year":"2011","unstructured":"Hempel D, Wojtukiewicz MZ, Koz\u0142owski L, et al. Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors. Tumour Biol. 2011;32(4):753\u20139.","journal-title":"Tumour Biol"},{"issue":"8","key":"2804_CR19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","volume":"20","author":"M Cavo","year":"2006","unstructured":"Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia. 2006;20(8):1341\u201352.","journal-title":"Leukemia"},{"issue":"1","key":"2804_CR20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/ph16010111","volume":"16","author":"G Kozalak","year":"2023","unstructured":"Kozalak G, B\u00fct\u00fcn \u0130, Toyran E, et al. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel). 2023;16(1):111.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"2804_CR21","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","volume":"14","author":"RZ Orlowski","year":"2008","unstructured":"Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14(6):1649\u201357.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2804_CR22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"KM Kortuem","year":"2013","unstructured":"Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121(6):893\u20137.","journal-title":"Blood"},{"issue":"17","key":"2804_CR23","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19(17):4559\u201363.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2804_CR24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953\u201364.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2804_CR25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/13543784.2015.1065250","volume":"24","author":"M Gentile","year":"2015","unstructured":"Gentile M, Offidani M, Vigna E, et al. Ixazomib for the treatment of multiple myeloma. Expert Opin Invest Drugs. 2015;24(9):1287\u201398.","journal-title":"Expert Opin Invest Drugs"},{"issue":"4","key":"2804_CR26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","volume":"58","author":"N Gupta","year":"2019","unstructured":"Gupta N, Hanley MJ, Xia C, et al. Clinical pharmacology of Ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet. 2019;58(4):431\u201349.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2804_CR27","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000570","volume":"4","author":"K Tzogani","year":"2019","unstructured":"Tzogani K, Florez B, Markey G, et al. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open. 2019;4(5): e000570.","journal-title":"ESMO Open"},{"issue":"17","key":"2804_CR28","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.3390\/molecules28176343","volume":"28","author":"J Zhang","year":"2023","unstructured":"Zhang J, Sun S, Liu J, et al. Discovery of a novel ubenimex derivative as a first-in-class dual CD13\/proteasome inhibitor for the treatment of cancer. Molecules. 2023;28(17):6343.","journal-title":"Molecules"},{"issue":"12","key":"2804_CR29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/acsmedchemlett.6b00217","volume":"7","author":"X Zhang","year":"2016","unstructured":"Zhang X, Adwal A, Turner AG, et al. New peptidomimetic boronates for selective inhibition of the chymotrypsin-like activity of the 26S proteasome. ACS Med Chem Lett. 2016;7(12):1039\u201343.","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"2804_CR30","first-page":"1139","volume":"62","author":"S Dan","year":"2002","unstructured":"Dan S, Tsunoda T, Kitahara O, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002;62(4):1139\u201347.","journal-title":"Cancer Res"},{"issue":"6","key":"2804_CR31","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.bmc.2012.01.017","volume":"20","author":"D Kong","year":"2012","unstructured":"Kong D, Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg Med Chem. 2012;20(6):1947\u201351.","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"2804_CR32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/aps.2010.150","volume":"31","author":"D Kong","year":"2010","unstructured":"Kong D, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin. 2010;31(9):1189\u20131197.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"2804_CR33","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205529","volume":"10","author":"X Peng","year":"2023","unstructured":"Peng X, Zhang S, Wang Y, et al. Stellettin B sensitizes glioblastoma to DNA-damaging treatments by suppressing PI3K-mediated homologous recombination repair. Adv Sci. 2023;10(3): e2205529.","journal-title":"Adv Sci"},{"issue":"1","key":"2804_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41392-023-01324-8","volume":"8","author":"X Peng","year":"2023","unstructured":"Peng X, Wang Y, Zhang S, et al. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair. Signal Transduct Target Ther. 2023;8(1):119.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2804_CR35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13046-021-02176-2","volume":"40","author":"X Peng","year":"2021","unstructured":"Peng X, Zhang S, Jiao W, et al. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021;40(1):374.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2804_CR36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41419-021-03805-6","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Peng X, Li X, et al. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021;12(6):546.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2804_CR37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-024-01978-0","volume":"23","author":"X Peng","year":"2024","unstructured":"Peng X, Huang X, Lulu TB, et al. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol Cancer. 2024;23(1):54.","journal-title":"Mol Cancer"},{"issue":"30","key":"2804_CR38","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202307747","volume":"11","author":"X Peng","year":"2024","unstructured":"Peng X, Huang X, Zhang S, et al. Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma. Adv Sci. 2024;11(30): e2307747.","journal-title":"Adv Sci"},{"issue":"2","key":"2804_CR39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"S Ito","year":"2020","unstructured":"Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel). 2020;12(2):265.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2804_CR40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, et al. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"2804_CR41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","volume":"8","author":"D Chauhan","year":"2005","unstructured":"Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8(5):407\u201319.","journal-title":"Cancer Cell"},{"issue":"3","key":"2804_CR42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1532\/IJH97.04107","volume":"80","author":"M Oancea","year":"2004","unstructured":"Oancea M, Mani A, Hussein MA, et al. Apoptosis of multiple myeloma. Int J Hematol. 2004;80(3):224\u201331.","journal-title":"Int J Hematol"},{"issue":"22","key":"2804_CR43","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells13221838","volume":"13","author":"M Mustafa","year":"2024","unstructured":"Mustafa M, Ahmad R, Tantry IQ, et al. Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. 2024;13(22):1838.","journal-title":"Cells"},{"issue":"5","key":"2804_CR44","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0002-9440(10)64779-7","volume":"157","author":"JC Reed","year":"2000","unstructured":"Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000;157(5):1415\u201330.","journal-title":"Am J Pathol"},{"issue":"5","key":"2804_CR45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53\u2013p21-RB signaling. Cell Death Differ. 2022;29(5):946\u201360.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2804_CR46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1083\/jcb.141.2.503","volume":"141","author":"J Brugarolas","year":"1998","unstructured":"Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol. 1998;141(2):503\u201314.","journal-title":"J Cell Biol"},{"key":"2804_CR47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63\u201371.","journal-title":"DNA Repair (Amst)"},{"key":"2804_CR48","first-page":"146","volume":"22","author":"M Alwahsh","year":"2023","unstructured":"Alwahsh M, Farhat J, Talhouni S, et al. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI J. 2023;22:146\u201368.","journal-title":"EXCLI J"},{"issue":"5","key":"2804_CR49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.12452","volume":"162","author":"JJ Gu","year":"2013","unstructured":"Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, et al. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol. 2013;162(5):657\u201369.","journal-title":"Br J Haematol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02804-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02804-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02804-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:40:23Z","timestamp":1751532023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02804-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02804-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal experiments were conducted in accordance with the guidelines for the care and use of laboratory animals, as approved by the Ethical Committee of Tianjin Medical University (TMUaMEC 2023036).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"235"}}